Stephen Collins, MD, PhD
President & Chief Executive Officer
Dr. Collins was formerly President and Chief Executive Officer of Insero Health, a developer of novel drugs for epilepsy and pain that was acquired by Biscayne Pharmaceuticals, where Dr. Collins also served as President and CEO. Previously, he was CEO of NeuroTherapeutics Pharma, a developer of novel CNS therapies, and Chief Scientific Officer and Vice President, Clinical Affairs at specialty pharmaceutical company Ovation Pharmaceuticals, where he oversaw research and development, won FDA approval for the orphan drugs Sabril® and Onfi®, and directed multiple late stage and post-approval development programs in oncology and neuroscience. Ovation was acquired by Lundbeck in 2009. Prior to Ovation, Dr. Collins was Global Senior Director of CNS and Pain at Johnson & Johnson, overseeing early-stage development of neurologic, pain and psychiatric agents. At Abbott Laboratories, Dr. Collins developed drugs for CNS and pain indications and contributed to the FDA approval of the epilepsy drugs Depakote ER® and Depacon®. He earned an AB degree in biophysics at the University of California, Berkeley and MD and PhD degrees at Case Western Reserve University. Dr. Collins completed residency and fellowship training at the University of California, San Francisco, where he also served on the faculty.
Samuel J. Reich
Mr. Reich is founder of the Reich Group, an early-stage biotechnology investment firm, and is a co-founder and Executive Chairman of drug developer Biscayne Pharmaceuticals. Previously, he served as Executive Vice President of OPKO Ophthalmologics. Earlier in his career, Mr. Reich was a founder and Executive Vice President of Acuity Pharmaceuticals, where he oversaw research and development, business development and intellectual property management. Mr. Reich was instrumental in completing financings totaling about $25 million for Acuity, and he subsequently helped engineer its successful acquisition by OPKO Health. Mr. Reich received a BA degree with high honors from Clark University, where he was Phi Beta Kappa, and later pursued doctoral studies in molecular biology at the University of Pennsylvania.
Director of Finance & Administration
Previously, Mr. Mendel was head of Finance and Administration at drug developer Biscayne Pharmaceuticals He began his career in finance as an investment analyst at Kawa Capital, a multi-strategy hedge fund that also engaged in real estate and private transactions. During his tenure, Mr. Mendel contributed to the fund’s growth from $30 million to +$300 million in assets under management. He received a Bachelor in Business Administration degree with a concentration in finance from the University of Miami.
Peter Goldstein, MS
Director of Research & Development, Neuroendocrine
Mr. Goldstein joined from Biscayne Pharmaceuticals, where he oversaw neuroendocrine research and development. Previously, Mr. Goldstein worked in the laboratory of Nobel laureate Dr. Andrew V. Schally, where he directed program management, performed preclinical research and advised on scientific and business matters. Earlier in his career, Mr. Goldstein helped direct product development and managed a global product line of advanced material components at Ceradyne, Inc. Mr. Goldstein graduated from the University of Florida with Bachelor and Master of Science degrees in materials science and engineering. He also completed doctoral research and course work in biomedical engineering at the University of Miami.
Joshua Johnstone, PhD
Director of Research & Development, CNS
Dr. Johnstone was previously Director of Research & Development, CNS, at Biscayne Pharmaceuticals, which he joined when it acquired CNS drug developer Insero Health. Dr. Johnstone was responsible for advancing the BIS-001 (huperzine A) program by investigating the agent’s unique signaling pathways and anti-epileptic effects. Previously, Dr. Johnstone was a post-doctoral fellow at the Veterans Affairs Medical Center in Miami, where he conducted research in glial biology and neurological disease. Dr. Johnstone received a BS degree from Washington State University and earned a PhD in neuroscience from the University of Miami Miller School of Medicine, where he conducted research investigating glial function and spinal cord injury.